Find alpha where nobody's looking
We provide institutional-quality research on the companies Wall Street won't cover.
Join thousands of investors hunting for edge in overlooked corners. Unsubscribe anytime.
Undiscovered Companies
We cover small-caps, micro-caps, and nano-caps — companies too small for Wall Street analysts to bother with.
Deep Analysis
Full company deep dives covering financials, competitive landscape, insider activity, and catalysts ahead.
Independent & Unbiased
No conflicts of interest. We never accept payment from the companies we cover. Period.
Asymmetric Upside
Small companies, big potential. Clear ratings, price targets, and risk assessments on every report.
Latest Reports
View allSensient Technologies: Hidden Compounder at Reasonable Price
Sensient Technologies is a specialty ingredients company that has quietly compounded returns for decades. Trading at reasonable valuations with strong pricing power and secular tailwinds in natural colors and flavors.
Prelude Therapeutics: JAK2/KAT6 Platform at Inflection Point
Prelude Therapeutics is a clinical-stage precision oncology company at a strategic inflection point following FDA IND clearance for PRT12396 (JAK2V617F inhibitor) and Incyte partnership. High-risk/high-reward microcap with validated targets.
Knorex: Agentic AI Buzzword Meets Ad-Tech Reality
KNRX surged 245% on an 'agentic AI' API launch, but underneath the buzzword sits $0.2M cash, $8.2M debt, shrinking revenue, and 2-3 weeks of runway. We break down why the narrative doesn't match the balance sheet.
Find alpha where nobody's looking
New small-cap, micro-cap, and nano-cap research delivered to your inbox. Free, forever.